University of Ulsan Foundation for Industry Cooperation

Enhancedbio Inc.

The Asan Foundation

Si Yeol Song

Eun Kyung Choi

Seong-Yun Jeong

Kyoung Jin Lee

Seok Soon Park

Eun Jin Ju

Eun Jung Ko

Jae Hee Lee

Seol Hwa Shin

Jinhyang Choi

Jaesook Park

Yun-Yong Park

The present invention relates to a biomarker composition for diagnosing radiation-resistant cancer comprising PMVK as an active ingredient and a method of diagnosing radiation-resistant cancer using the same, and when the PMVK is knocked down, it is confirmed that the survival rate of cancer cells decreases during radiation treatment, and based on this, the possibility as a factor related to radiation therapy resistance to cancer was suggested, and the PMVK can be used as a new target to enhance the effect of radiation therapy on human cancer cells.

Enhancing radiation sensitivity comprising administering PMVK inhibiting siRNA and shRNA

Provided is a peptide for targeting gastric cancer, a composition for diagnosing radioresponsiveness-dependent gastric cancer using the peptide, and a drug delivery use of the peptide, wherein a functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients.

Peptides for targeting gastric cancer, and medical use tehreof

Provided is a peptide for targeting colorectal cancer, a composition for diagnosing radioresponsiveness-dependent prognosis of colorectal cancer using the peptide, and a drug delivery use of the peptide, wherein a functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, in consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients.

Peptides for targeting colorectal cancer, and medical use thereof

Growing community of inventors

Seoul, South Korea

Si Yeol Song